SEC Form 4 · accession 0001104659-16-148695
Neos Therapeutics, Inc. · NEOS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vipin K Garg
Officer — Chief Executive Officer · Director
Period of report
Sep 30, 2016
Accepted (ET)
Oct 4, 2016 · 7:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001467652
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $10.74 | Sep 30, 2016 | A | 62,500 | A | — | Apr 1, 2026 | Common Stock | 62,500 | 87,500 | D |
Explanation of responses
- F1On April 1, 2016, the reporting person was granted performance based options to purchase 75,000 shares of stock. The option vests in four equal, annual installments beginning on April 1, 2017, provided that certain performance based metrics have been met or satisfied on or before September 30, 2016, of which the performance criteria were met with respect to 62,500 shares.